NM_021922.3:c.31G>A

Variant summary

Our verdict is Likely benign. The variant received -4 ACMG points: 0P and 4B. BP4_Strong

The NM_021922.3(FANCE):​c.31G>A​(p.Ala11Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000424 in 1,333,328 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.00025 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00045 ( 0 hom. )

Consequence

FANCE
NM_021922.3 missense

Scores

4
15

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:4

Conservation

PhyloP100: -0.344

Publications

2 publications found
Variant links:
Genes affected
FANCE (HGNC:3586): (FA complementation group E) The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group E. [provided by RefSeq, Jul 2008]
FANCE Gene-Disease associations (from GenCC):
  • Fanconi anemia complementation group E
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, G2P
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -4 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.028799146).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
FANCENM_021922.3 linkc.31G>A p.Ala11Thr missense_variant Exon 1 of 10 ENST00000229769.3 NP_068741.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
FANCEENST00000229769.3 linkc.31G>A p.Ala11Thr missense_variant Exon 1 of 10 1 NM_021922.3 ENSP00000229769.2
FANCEENST00000696264.1 linkc.31G>A p.Ala11Thr missense_variant Exon 1 of 8 ENSP00000512511.1
FANCEENST00000648059.1 linkn.31G>A non_coding_transcript_exon_variant Exon 1 of 11 ENSP00000497902.1
FANCEENST00000696265.1 linkn.31G>A non_coding_transcript_exon_variant Exon 1 of 9 ENSP00000512512.1

Frequencies

GnomAD3 genomes
AF:
0.000250
AC:
38
AN:
151962
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000725
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000328
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.000378
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000383
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000137
AC:
8
AN:
58348
AF XY:
0.0000580
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000297
Gnomad ASJ exome
AF:
0.000186
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000266
Gnomad NFE exome
AF:
0.000137
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000446
AC:
527
AN:
1181254
Hom.:
0
Cov.:
30
AF XY:
0.000394
AC XY:
226
AN XY:
574032
show subpopulations
African (AFR)
AF:
0.0000803
AC:
2
AN:
24900
American (AMR)
AF:
0.000507
AC:
10
AN:
19730
Ashkenazi Jewish (ASJ)
AF:
0.0000513
AC:
1
AN:
19492
East Asian (EAS)
AF:
0.0000370
AC:
1
AN:
26992
South Asian (SAS)
AF:
0.0000229
AC:
1
AN:
43748
European-Finnish (FIN)
AF:
0.000276
AC:
7
AN:
25372
Middle Eastern (MID)
AF:
0.000876
AC:
3
AN:
3424
European-Non Finnish (NFE)
AF:
0.000504
AC:
489
AN:
969998
Other (OTH)
AF:
0.000273
AC:
13
AN:
47598
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.484
Heterozygous variant carriers
0
28
57
85
114
142
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000250
AC:
38
AN:
152074
Hom.:
0
Cov.:
33
AF XY:
0.000215
AC XY:
16
AN XY:
74356
show subpopulations
African (AFR)
AF:
0.0000723
AC:
3
AN:
41516
American (AMR)
AF:
0.000327
AC:
5
AN:
15284
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5166
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4830
European-Finnish (FIN)
AF:
0.000378
AC:
4
AN:
10574
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
292
European-Non Finnish (NFE)
AF:
0.000383
AC:
26
AN:
67916
Other (OTH)
AF:
0.00
AC:
0
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.520
Heterozygous variant carriers
0
2
4
5
7
9
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000486
Hom.:
0
Bravo
AF:
0.000193
ExAC
AF:
0.0000774
AC:
3

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Fanconi anemia complementation group E Uncertain:3
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. -

Dec 29, 2023
Fulgent Genetics, Fulgent Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 11 of the FANCE protein (p.Ala11Thr). This variant is present in population databases (rs753304968, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with FANCE-related conditions. ClinVar contains an entry for this variant (Variation ID: 408158). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The threonine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

FANCE-related disorder Uncertain:1
Jul 24, 2024
PreventionGenetics, part of Exact Sciences
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

The FANCE c.31G>A variant is predicted to result in the amino acid substitution p.Ala11Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.035% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.079
BayesDel_addAF
Benign
-0.46
T
BayesDel_noAF
Benign
-0.53
CADD
Benign
7.5
DANN
Uncertain
0.98
DEOGEN2
Benign
0.072
T
Eigen
Benign
-1.2
Eigen_PC
Benign
-1.3
FATHMM_MKL
Benign
0.038
N
LIST_S2
Benign
0.39
T
M_CAP
Benign
0.044
D
MetaRNN
Benign
0.029
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
1.2
L
PhyloP100
-0.34
PrimateAI
Uncertain
0.75
T
PROVEAN
Benign
-0.63
N
REVEL
Benign
0.028
Sift
Uncertain
0.022
D
Sift4G
Uncertain
0.016
D
Polyphen
0.0010
B
Vest4
0.075
MutPred
0.080
Gain of glycosylation at A11 (P = 0.0162);
MVP
0.39
MPC
0.10
ClinPred
0.052
T
GERP RS
-3.7
PromoterAI
0.086
Neutral
Varity_R
0.055
gMVP
0.20
Mutation Taster
=99/1
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs753304968; hg19: chr6-35420353; API